Atypical antipsychotics for older adults: Are they safe and effective as we once thought?

Journal of Comparative Effectiveness Research

Volumn 2, Issue 4, 2013, Pages 355-358

  Jeste, Dilip V ^a   Maglione, Jeanne E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGED; AGING; AROMATHERAPY; BALNEOTHERAPY; BIPOLAR DISORDER; CEREBROVASCULAR ACCIDENT; DANCE THERAPY; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FAMILY; HEALTH CARE COST; HEALTH CARE FACILITY; HUMAN; MOOD DISORDER; MORTALITY; MUSIC THERAPY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RELAXATION TRAINING; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SOCIAL INTERACTION; SUPPORT GROUP; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT;

EID: 84886944809     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.13.33     Document Type: Review

References (20)

1. Hofer A, Rettenbacher MA, Widschwendter CG, Kemmler G, Hummer M, Fleischhacker WW. Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. Eur. Arch. Psychiatry Clin. Neurosci. 256(4), 246-255 (2006).
2. Matsui T, Nakaaki S, Murata Y etal. Determinants of the quality of life in Alzheimer's disease patients as assessed by the Japanese version of the quality of life-Alzheimer's disease scale. Dement. Geriatr. Cogn. Disord. 21(3), 182-191 (2006).
3. Svirskis T, Korkeila J, Heinimaa M etal. Quality of life and functioning ability in subjects vulnerable to psychosis. Compr. Psychiatry 48(2), 155-160 (2007).
4. Fuh JL, Liu CK, Mega MS, Wang SJ, Cummings JL. Behavioral disorders and caregivers' reaction in Taiwanese patients with Alzheimer's disease. Int. Psychogeriatr. 13(1), 121-128 (2001).
5. Yaffe K, Fox P, Newcomer R etal. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 287(16), 2090-2097 (2002).
6. Buhr GT, Kuchibhatla M, Clipp EC. Caregivers' reasons for nursing home placement: clues for improving discussions with families prior to the transition. Gerontologist 46(1), 52-61 (2006).
7. Murman DL, Colenda CC. The economic impact of neuropsychiatric symptoms in Alzheimer's disease: can drugs ease the burden? Pharmacoeconomics 23(3), 227-242 (2005).
8. Jeste DV, Alexopoulos GS, Bartels SJ etal. Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next two decades. Arch. Gen. Psychiatry 56(9), 848-853 (1999).
9. Jin H, Shih PA, Golshan S etal. Comparison of longer-term safety and effectiveness of 4atypical antipsychotics in patients over age 40: atrial using equipoise-stratified randomization. J.Clin. Psychiatry 74(1), 10-18 (2013).
10. Maher AR, Theodore G. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J.Manag. Care Pharm. 18(5SUPPL.B), S1-S20 (2012).
11. Weiss E, Hummer M, Koller D, Ulmer H, Fleischhaker WW. Off-label use of antipsychotic drugs. J.Clin. Psychopharmacol. 20(6), 695-698 (2000).
12. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: asystematic review. Schizophr. Res. 71(2-3), 195-212 (2004).
13. Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug. Saf. 22(3), 195-214 (2000).
14. Jeste DV. Tardive dyskinesia in older patients. J.Clin. Psychiatry 61(4), 27-32 (2000).
15. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am. J.Psychiatry 157(7), 1150-1155 (2000).
16. Maher AR, Maglione M, Bagley S etal. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306(12), 1359-1369 (2011).
17. Jeste DV, Jin H, Golshan S etal. Discontinuation of quetiapine from an NIMH-funded trial due to serious adverse events. Am. J.Psychiatry 166(8), 937-938 (2009).
18. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am. J.Geriatr. Psychiatry 14(3), 191-210 (2006).
19. O'Connor DW, Ames D, Gardner B, King M. Psychosocial treatments of behavior symptoms in dementia: a systematic review of reports meeting quality standards. Int. Psychogeriatr. 21(225), 240 (2009).
20. Jeste DV, Blazer D, Casey DE etal. ACNP white paper: update on the use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 33(5), 957-970 (2008).